Image Image Image Image Image Image Image Image Image Image
Доступ
Идти наверх

Идти наверх

MACBETH. Phase IV Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy
19/03/2014

Foto1_def2
Description

Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors

If you are interested in taking part in a clinical trial, please call us at 935 950 155 and we will assess whether you are eligible. Further information on trials at research projects

Интравитреальные инъекцииЭкссудативная или влажная ВМД

Author

Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Директор
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела

Last modified: 22 July, 2019 - 13:01